[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dental-erosion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dental-erosion":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100648268","salivary-function-and-dental-changes-during-glp-1-therapy-100648268",false,"NCT07720466","Salivary Function and Dental Changes During GLP-1 Therapy","Prospective Evaluation of Salivary Calcium Levels, Salivary Function, and Dental Hard Tissue Changes in Patients Receiving GLP-1 Receptor Agonist Therapy","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Body mass index (BMI) ≥27 kg\u002Fm².\n* Clinical decision by an endocrinologist to initiate semaglutide or tirzepatide therapy for obesity management.\n* No previous treatment with GLP-1 receptor agonists.\n* Willingness to participate and ability to provide written informed consent.\n* Willingness to attend both the baseline and 3-month follow-up visits.\n\nExclusion Criteria:\n\n* Previous use of any GLP-1 receptor agonist.\n* History of head and neck radiotherapy.\n* Sjögren syndrome or other systemic diseases affecting salivary gland function.\n* Chronic kidney disease.\n* Pregnancy or breastfeeding.\n* Use of medications known to markedly affect salivary secretion.\n* Active orthodontic treatment.\n* Severe dental erosion requiring restorative treatment at baseline.\n* Edentulism or the absence of anterior teeth required for dental hard tissue assessment.\n* Inability or unwillingness to comply with the study protocol or attend the 3-month follow-up visit.\n* History of eating disorders associated with recurrent self-induced vomiting (e.g., bulimia nervosa).\n* Medical conditions causing persistent vomiting or severe gastroesophageal disease unrelated to GLP-1 therapy.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","OBSERVATIONAL","People who use glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, may experience changes in their oral health. Some people report dry mouth, changes in saliva, and increased wear of their teeth after starting these medicines. However, little is known about whether these medicines affect saliva and dental hard tissues.\n\nThe purpose of this study is to evaluate changes in salivary calcium levels, salivary function, and dental hard tissues in adults who begin treatment with semaglutide or tirzepatide for obesity.\n\nApproximately 40 participants will be enrolled before starting GLP-1 receptor agonist therapy. Oral examinations, standardized intraoral photographs, saliva samples, and body weight measurements will be obtained before treatment and again after three months. Saliva samples will be analyzed for calcium concentration, pH, and salivary flow rate. Dental hard tissue changes will be assessed using the Basic Erosive Wear Examination (BEWE) index.\n\nThe findings from this study may improve understanding of the effects of GLP-1 receptor agonists on oral health and help healthcare professionals identify and prevent possible dental complications during treatment.",[24,25,26,27],"Obesity","Dental Erosion","Saliva Collection","Saliva Altered","NOT_YET_RECRUITING","2026-07-17",{"date":31,"type":32},"2026-07-22","ACTUAL",{"date":34,"type":20},"2026-08-17",{"date":36,"type":20},"2027-03-17",{"name":38,"class":39},"Bilecik Seyh Edebali Universitesi","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100408753","obesity-and-oral-diseases-in-adult-patients-100408753","NCT04602572","Obesity and Oral Diseases in Adult Patients","ObOd","Inclusion Criteria:\n\n* Obese adult patients.\n* Patients referred to the Obesity Clinic at the Hospital.\n\nExclusion Criteria:\n\n* Unwillingness to participate.","20 Years","70 Years",{"count":51,"type":20},400,"Overweight and obesity are among the major chronic disorders of the 21st century and one of the fastest growing health problems worldwide. Obesity is accompanied by a state of low-grade inflammation which may contribute to the occurrence of diabetes mellitus, cardiovascular disease, hypertension, stroke, and certain cancers. Furthermore, obesity has been associated with oral health problems as hyposalivation, dental caries and periodontitis.\n\nThe management and treatment of obesity is outlined in clinical guidelines from American Association of Clinical Endocrinologists\u002FAmerican College of Endocrinology and European Association for the Study of Obesity. The cornerstone is life-style modification programs aiming to reduce energy intake and increase physical activity, referred to as conservative treatment. All patients must undergo a thorough systematic work-up. The work-up concludes in a final multi-disciplinary meeting with a concrete individualized plan on how sustained weight-loss is to be achieved; either by a non-surgical or a surgical approach (Bariatric surgery).\n\nPeriodontitis is cited to be the sixth most prevalent chronic condition globally. The mechanisms by which obesity affects the periodontal tissues is poorly understood, and the understanding of the key role of adipocytes in the inflammatory response to infections is crucial in comprehending how periodontal disease susceptibility may be modified in obese individuals.\n\nThe main objectives of the present research project are to explore the association between obesity and oral diseases and further, to assess how weight changes following non-surgical and surgical interventions of obese patients may affect the cariological and periodontal health status.\n\nFour hundred patients referred to the Obesity Centre at Haukeland University Hospital, Norway will consecutively be screened and invited to participate in this prospective cohort study. At baseline, detailed medical and oral data will be obtained from health forms, questionnaires, clinical examinations, and by consulting the patient's care team. Following baseline examination, all patients will undergo a thorough systematic work-up consisting av interviews and consultations concluding in a final multi-disciplinary individualized non-surgical or surgical treatment plan on how sustained weight-loss can be achieved. New sets of medical, oral, and molecular data will be collected at 3-, 12- and 18-month following non-surgical\u002Fsurgical interventions.",[24,54,55,56,25],"Oral Diseases","Periodontitis","Dental Caries",[24,58,55,59,60,61],"Overweight","Caries","Bariatric surgery","Oral health","2026-05-04",{"date":64,"type":32},"2026-05-08",{"date":66,"type":20},"2026-11-01",{"date":68,"type":20},"2027-12-31",{"name":70,"class":39},"University of Bergen"]